Aphena Pharma Solutions-Tennessee, LLC

Aphena Pharma Solutions-Tennessee, LLC, a self-certified small disadvantaged business, supplies pharmaceutical repackaging, distribution, and inventory management services exclusively to the Department of Veterans Affairs as a prime contractor on a full-and-open basis, with no participation in set-aside categories across its federal footprint.

The company operates as a subsidiary of Aphena Pharma Solutions Holdings, Inc., headquartered in Cookeville, Tennessee, and manufactures unit-of-use pharmaceutical packages from bulk pharmaceuticals, with monthly repackaging capacity of up to 300,000 bottles. Aphena Pharma serves the VA's Consolidated Mail Outpatient Pharmacy program, which covers approximately 140 VA healthcare facilities nationwide. The vendor competes in open market conditions across NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers) and PSC codes for pharmaceutical services and packaging labor. Recent representative work includes a $7.2 million firm-fixed-price delivery order from Veterans Integrated Service Network 15 issued May 1, 2026, for pharmaceutical repacking supporting the national CMOP program through October 31, 2026, with place of performance in Cookeville; a $33.5 million firm-fixed-price delivery order from VISN 15 issued April 30, 2025, for pharmaceutical repackaging services with ultimate completion April 29, 2026; and a $490.9 million firm-fixed-price delivery order from the VA National Acquisition Center issued July 14, 2023, for repackaging program services through September 30, 2024.

Aphena Pharma's customer base is highly concentrated within the Department of Veterans Affairs. The top five customer segments account for approximately 65% of all recent awards by count. VISN 15 dominates both award volume and dollar value—807 awards with $701 million combined potential value—followed by the VA National Acquisition Center (43 awards, $76.9 million), VISN 12 (172 awards, $61.7 million), the Centers for Disease Control and Prevention Pittsburgh (10 awards, $25.2 million), and VISN 9 (378 awards, $14.6 million). This concentration reflects Aphena Pharma's specialization in VA pharmaceutical operations; the source data spans 23 distinct federal agencies, but the vast majority of revenue derives from Veterans Health Administration contracts. Of the combined potential value across all awards, approximately $701 million—or 71% of the total $982.4 million portfolio—comes from VISN 15 alone.

The vendor holds five principal parent indefinite-delivery contracts. The Indefinite Delivery Contract V797P8100 supports 989 task orders with $47.7 million combined potential value; IDC VA797M12D0017 carries 661 task orders and $53.6 million; IDC V797P9191 covers 510 task orders and $47.5 million; IDC 36C77020D0001 includes 144 task orders and $101.3 million combined potential value; and IDC VA797P0271 hosts 109 task orders and $21.6 million. Two single-award IDCs awarded directly to Aphena Pharma—one valued at $17.5 million from the VA National Acquisition Center (September 2022 to August 2025) and a larger contract worth $383.5 million from VISN 15 (November 2019 to October 2024)—anchor the vendor's contracting posture and generate the majority of task-order activity.

Activity has remained relatively flat over the past five years (2022: 29 awards; 2023: 31; 2024: 31; 2025: 16; 2026: 2 to date), with the decline in 2025 and 2026 reflecting incomplete-year capture in the source. Only one award faces ultimate completion within the next twenty-four months—the May 1, 2026 IDC from VISN 15 with a $7.2 million ceiling and October 31, 2026 completion date—posing minimal recompete cliff risk relative to the vendor's total portfolio.

The Service Contract Inventory dataset captures a subset of Aphena Pharma's federal activity above the $150,000 reporting threshold for service contracts, excluding goods and products. SCI-reported invoicing totaled $27.5 million across FY2022–FY2024, with FY2022 at $4.9 million (25.9 FTEs), FY2023 at $10.5 million (55.7 FTEs), and FY2024 at $12.2 million (65.0 FTEs). These figures represent only federal service contracts and are a strict subset of the vendor's total federal revenue, which includes substantial goods procurements and product sales not captured in SCI. Government-paid hourly rates on SCI-reportable prime contracts run uniformly at approximately $90.28 per hour across the 10th, median, and 90th percentiles, indicating standardized labor pricing across Aphena Pharma's service delivery. The vendor performs 100% of labor on its prime contracts with zero subcontract hours reported in SCI, reflecting a fully internal delivery model.

Aphena Pharma operates exclusively as a prime contractor—2,889 awards (100%) are prime, with zero sub-awards in the source dataset. The company does not appear as a named subcontractor on other federal contracts. This posture reflects the vendor's role as a specialized incumbent serving the VA's pharmaceutical supply chain directly, rather than as a feeder or teaming partner to larger integrators. The award portfolio is dominated by two work categories: Packaging and Labeling Services (1,963 awards) and General Warehousing and Storage (659 awards), accounting for 91% of award volume. Medical-Other PSC codes (1,433 awards) and Drugs and Biologicals (798 awards) represent 78% of the portfolio by PSC classification, confirming the vendor's tight focus on pharmaceutical logistics and distribution for veterans' healthcare.